Introduction: Comorbidities are common among cancer patients and with an aging population are becoming more prevalent. These can potentially affect the stage at diagnosis, treatment and outcomes of people with cancer. Despite the intimate relationship between comorbidity and cancer, there is limited consensus on how to record, interpret or manage comorbidities in the context of cancer. Addressing the impact of comorbid conditions in cancer patients warrants improvement in the evidence base from which to make treatment decisions for those with comorbidities. Methods: In this prospective study, 64 patients with breast cancer, underwent QOL assessment using FACT -B questionnaire at three time points-pre-radiation and three and six months post radiation. Results: 29(46%) patients had comorbidities of which 23 (35%) had cardiovascular comorbidities and 6 had other comorbidities. The co-morbidities were negatively associated with multiple domains of quality of life, including physical functioning, general health, bodily pain. Patients with diabetes and hypertension had significantly lower scores in physical functioning in comparison to patients without diabetes and hypertension, but improved after treatment. In majority of patients the overall scores were less in patients with co-morbidities compared to patients without any comorbidity. Conclusion: Comorbidities can significantly affect the quality of life in patients with comorbidities. Hence greater research into the QOL issues for better patient care and symptom management especially during the transitioning phase from active care to follow up will help clinicians improve the quality of care and interdisciplinary co-ordination.
INTRODUCTION
Comorbidity is defined as the coexistence of disorders in addition to a primary disease of interest. Comorbidities are common among cancer patients and with an aging population are becoming more prevalent [1] . These can potentially affect the stage at diagnosis, treatment and outcomes of people with cancer. Despite the intimate relationship between comorbidity and cancer, there is limited consensus on how to record, interpret or manage comorbidities in the context of cancer. Patients with comorbidities are often less likely to receive treatment with curative intent. Evidence in this area is lacking because of the frequent exclusion of patients with comorbidities from randomized trials. Cancer itself is a chronic disease with long term consequences for health and quality of life and is more prevalent among older people. The coexistence of cancer and other chronic diseases has substantial implications for treatment decisions and treatment outcomes for both cancer and chronic disease. There are several reasons that may explain the impact of comorbidity on treatment uptake. Clinicians may be concerned that concomitant conditions will increase the toxicity and side effects of treatment, that treatments may be less effective in these groups, or that the life expectancy of these patients is insufficient to justify the use of potentially toxic agents. It is also possible that these patients themselves are more likely to decline treatment.
Breast cancer is the most commonly diagnosed cancer among women worldwide. It has been reported that each year over 1.1 million women worldwide are diagnosed with breast cancer and 410,000 die from the disease [2] .Many breast cancer patients have co existent chronic diseases or co-morbidities at the time of their cancer diagnosis. Women with breast cancer have similar risks as those without cancer for developing chronic illness or co-morbidities due to natural effects of aging [3] . However cancer survivors are at risk for chronic conditions such as obesity, hypertension,
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Monica Irukulla, Rama Vaghmare, Deepa Joseph, Syed Fayaz Ahmed, Jyothi Jonnadula, Deepthi Valiyaveettil diabetes, dyslipidemia and decreased bone mass not only because of the natural aging process, but sometimes due to the late effects of cancer treatment [4] .
Addressing the impact of comorbid conditions in cancer patients warrants improvement in the evidence base from which to make treatment decisions for those with comorbidities. This in turn requires improvement in the measurement of comorbidities, improving integration and coordination of care, preventing the occurrence of new comorbidities and limiting exacerbations of existing conditions [6] . This will lead to development of better clinical decision making tools and strengthen research collaborations between specialties.
MATERIALS & METHODS:
We conducted a prospective study in patients of breast cancer who reported for receiving adjuvant radiation therapy. Structured interview tool was used to gather demographic, medical, and clinical information regarding breast cancer diagnosis, stage of disease, type of surgery and chemotherapy and the complications. Comorbidities were self-reported by the patients at the time of cancer diagnosis and prior to cancer treatment.
Quality of life was assessed with the help of FACT B scale [7] at three points of time, baseline (before starting radiation) and at 3 and 6 months post completion of radiation. Characteristics of the participants were summarized using descriptive studies (means, standard deviations for continuous variables, and frequency distributions, and proportions for qualitative variables. All statistical tests were conducted at the 0.05 significance levels.
At baseline and at 3months post radiation there were 64 patients available for analysis and at 6 months after the treatment only 60 patients were available for analysis. 3 patients developed metastatic disease within six months and one patient could not be assessed.
The median age at diagnosis was 52.5 years, ranging from 29 years to 86 years. 42 (81%) women were married, 10 (16%) were widowed, 2 (3%) were unmarried. 22 patients (34.3%) were obese (BMI>25) and 21 (32%) were overweight (BMI 23-24.9).The disease was left sided in 52% , right sided in 42% , bilateral in 6% patients. 76% patients underwent mastectomy, 24% patients had undergone breast conserving surgery. Infiltrating ductal carcinoma (IDC) was the predominant histopathological finding in 89% cases. 53 (83%) patients received adjuvant chemotherapy. 5 patients received neo adjuvant chemotherapy. No chemotherapy was given in six patients of which three patients did not receive chemotherapy due to comorbidities.
There were no associated comorbidities in 35(54%) patients. 29 (46%) patients had co-morbidities like diabetes mellitus (DM), hypertension, coronary artery disease or thyroid disorders. One patient had Wolf Parkinson White syndrome and one had rheumatic heart disease. 23 patients had cardiac co-morbidities, 6 had other co-morbidities. Among 64 patients predominant co morbidity was DM in 30% patients, hypertension in 28% patients, arthritis in 15% patients, 7% had thyroid problems. 13(20.3%) had more than one comorbidity .The comorbidities were self-assessed and did not change during treatment or until six months post radiation. The demographic data and few relevant parameters are given in the Table I. No significant difference in the physical and functional well being was observed between baseline and post treatment scores. Emotional well being and symptoms like pain, and upset by hair loss, systemic therapy side effects improved significantly during follow up. There was deterioration in the social well being scores compared to pre treatment which was statistically not significant. The arm symptoms were increased compared to baseline and persisted. Impaired body image and decrease in the sexual functioning was observed in all patients. There was moderate distress due to fear of cancer recurrence and resuming normal life. Fatigue was predominant especially in the first and second week of RT treatment. Majority of patients (70%) reported that fatigue decreased in intensity but was sustained even at 3 and 6 months following treatment. The comparison of all the scores is given in the Table II The comorbidities were negatively associated with multiple domains of quality of life including physical functioning, general health and bodily pain. Emotional and functional well being were improved (p=0.001 and p=0.002 respectively). The scores is in patients with comorbidities is shown in the Table III Patients with diabetes and hypertension had significantly lower scores in physical functioning in comparison to patients without diabetes and hypertension, but they improved after treatment. The overall scores were lower in patients with comorbidities compared to patients without any comorbidity. The scores of the patients without comorbidities are shown in Table IV .
The scores for physical well being, emotional well being, functional well being and additional concerns were improved with statistically significant differences for functional well being and additional concerns (p<0.001 and p=0.013 respectively). Emotional well being scores improved (p=0.067). The total FACT B scores improved compared to baseline (p=0.081) At Pre RT (Baseline) of total 23 patients with cardiac comorbidity, 19 (82%) had FACT B score <100, 4 (18%) had score >100. At 3 months, 15 patients (65%) had scores <100 and 8(35%) had a score of >100. At 6 months, 11 patients (48%) had scores <100 and 12 patients (52%) had a score >100. In patients with comorbidities all the scores were improved compared to baseline with physical well being, functional well being and additional concerns being statistically significant (p values of 0.025, 0.01 and 0.003 respectively). The graphical representation of the mean scores of patients with and without comorbidities is shown in Graph I. [8] . A few studies have reported that cancer survivors with high chronic disease burden or comorbidities report lower physical and social functioning [9, 10] .
Quality of life data in metastatic breast cancer patients was found to be prognostic and predictive of survival time. Psychological distress-anxiety and depression were found to be common among breast cancer patients even years after their diagnosis and treatment. Psychological factors also were found to predict subsequent quality of life or even overall survival in breast cancer patients [11] . Supportive care-interventions such as counseling, providing social support and exercise can potentially improve quality of life. Symptoms like pain, fatigue, arm edema and menopausal symptoms are commonly reported by breast cancer patients. Recognition and management of these symptoms is an important issue as such symptoms impair health-related quality of life. Breast cancer patients especially in younger age groups suffer from poor sexual functioning that can negatively affect quality of life. Assessing quality of life in cancer patients could contribute to improved treatment outcomes and serve as prognostic markers [12] . 
